Aclaris Therapeutics, Inc.
ACRS
NASDAQ·Healthcare·Biotechnology·Mkt cap $861.7M
$6.17
▲ +3.70%
P/E
-10.64
Mkt Cap
$861.7M
52-Wk Range
$1.74–$6.60
52-Week Range
$1.74 - $6.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 196.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized pipeline of innovative immune-inflammatory disease treatments
- Proprietary drug development platform
- Diverse clinical-stage research portfolio
- Targeted approach to unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Revenue decline expected
Advancing clinical trials for key drug candidates
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+41.5% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ACRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.15 vs -$0.16 consensus (+6.3% surprise). Revenue of $1.6M vs $1.4M expected (+17.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.3%
Revenue trend · last 8Q
—
-48%
-39%
-36%
-24%
-86%
+37%
-8%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.3M
$9.2M
$1.5M
$1.8M
$3.3M
$1.3M
$2.0M
$1.6M
Margins · last 8Q
Gross
85.8%
Profit
-1320.1%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · $12.00 · May 5, 2026
vs Industry
How ACRS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related